ORGANOGENESIS HOLDINGS INC. Operating Lease Cost
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Operating Lease Cost of $10.21 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-02-26
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for the quarter ending 2024-06-30 was $2.16M, a 13.14% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for the quarter ending 2024-03-31 was $2.20M, a 3.84% decline year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for the quarter ending 2023-12-31 was $2.67M, a 12.31% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for the quarter ending 2023-09-30 was $2.61M, a 9.17% increase year-over-year.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for fiscal 2025 was $10.21M, a 7.78% increase from fiscal 2024.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for fiscal 2024 was $9.47M, a 5.75% decline from fiscal 2023.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for fiscal 2023 was $10.05M, a 5.04% increase from fiscal 2022.
- ORGANOGENESIS HOLDINGS INC. operating lease, cost for fiscal 2022 was $9.57M, a 35.44% increase from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.21M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $9.47M 10-K · filed 2026-02-26 | |||
| 2024-06-30 | $2.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.36M 10-Q · filed 2024-08-08 | $7.03M derived: sum of 3 quarters · filed 2026-02-26 | $9.64M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.20M 10-Q · filed 2024-05-09 | $4.87M derived: sum of 2 quarters · filed 2026-02-26 | $7.48M derived: sum of 3 quarters · filed 2026-02-26 | $9.96M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $2.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.27M derived: sum of 2 quarters · filed 2026-02-26 | $7.76M derived: sum of 3 quarters · filed 2026-02-26 | $10.05M 10-K · filed 2026-02-26 |
| 2023-09-30 | $2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.10M derived: sum of 2 quarters · filed 2024-08-08 | $7.39M 10-Q · filed 2023-11-09 | $9.76M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-06-30 | $2.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.78M 10-Q · filed 2024-08-08 | $7.15M derived: sum of 3 quarters · filed 2024-08-08 | $9.54M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $2.29M 10-Q · filed 2024-05-09 | $4.66M derived: sum of 2 quarters · filed 2024-05-09 | $7.05M derived: sum of 3 quarters · filed 2024-05-09 | $9.43M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $4.76M derived: sum of 2 quarters · filed 2024-02-29 | $7.14M derived: sum of 3 quarters · filed 2024-02-29 | $9.57M 10-K · filed 2024-02-29 |
| 2022-09-30 | $2.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $4.76M derived: sum of 2 quarters · filed 2023-11-09 | $7.20M 10-Q · filed 2023-11-09 | $9.39M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $4.81M 10-Q · filed 2023-08-09 | $7.00M derived: sum of 3 quarters · filed 2023-08-09 | $8.86M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $2.43M 10-Q · filed 2023-05-10 | $4.63M derived: sum of 2 quarters · filed 2023-05-10 | $6.49M derived: sum of 3 quarters · filed 2023-05-10 | $8.22M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $2.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $4.05M derived: sum of 2 quarters · filed 2023-03-01 | $5.79M derived: sum of 3 quarters · filed 2023-03-01 | $7.07M 10-K · filed 2023-03-01 |
| 2021-09-30 | $1.86M 10-Q · filed 2021-11-09 | $3.59M derived: sum of 2 quarters · filed 2021-11-09 | $4.87M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $1.74M 10-Q · filed 2021-08-09 | $3.02M 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $1.28M 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |